Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Accumulated Expenses (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Accumulated Expenses for 5 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 79.51% year-over-year to $6.6 million, compared with a TTM value of $6.6 million through Dec 2025, down 79.51%, and an annual FY2025 reading of $6.6 million, down 79.51% over the prior year.
  • Accumulated Expenses was $6.6 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $30.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $44.7 million in Q1 2024 and bottomed at $4.9 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $20.4 million, with a median of $17.7 million recorded in 2025.
  • The sharpest move saw Accumulated Expenses plummeted 83.72% in 2022, then skyrocketed 692.31% in 2024.
  • Year by year, Accumulated Expenses stood at $8.9 million in 2021, then surged by 237.73% to $30.1 million in 2022, then fell by 7.92% to $27.7 million in 2023, then rose by 16.69% to $32.4 million in 2024, then tumbled by 79.51% to $6.6 million in 2025.
  • Business Quant data shows Accumulated Expenses for KNSA at $6.6 million in Q4 2025, $30.9 million in Q3 2025, and $13.2 million in Q2 2025.